



*International Pharmaceutical
Manufacturers Group*

ANNUAL REPORT



June 2021



Photo by The Tonik on Unsplash

Table of Contents

2

Foreword

4

Chairman's
Message

6

Vision, Mission,
Role, and
Commitment
(COVID-19)

8

Governance

9

Board
Composition

10

The Secretariat

11

Activities and
Contributions of
Sub-Committees
and Task Forces

32

Our Activities in
2020

34

IPMG in the Media

38

Glossary



Foreword

IPMG at a Glance

Established in August 2002, IPMG is a non-profit association of international R&D-based pharmaceutical companies operating in Indonesia. IPMG currently represents 24 companies that are committed to researching, developing, manufacturing, and marketing safe and high-quality medicines.

As a partner and supporter of the government's efforts to improve the healthcare system in Indonesia and to provide all Indonesians with access to innovative, safe and high-quality international-standard medicines, IPMG works with the medical community in a scientific manner and complies with all relevant laws and regulations. Our members are multinational companies that are good corporate citizens

committed to actively supporting community health programs and public education on diseases and promoting healthcare throughout Indonesia.

IPMG communicates the role and contribution of R&D-based pharmaceutical manufacturers by helping people improve their quality of life, as well as pushing for advancement of an effective and integrated healthcare system in Indonesia.

The group represents the views of its members in discussions with the government and other stakeholders about healthcare issues. IPMG maintains close contact—and works closely—with the government, parliamentarians, academics, professional bodies, health organizations, the



media, and other partners in a continuous effort to improve Indonesia's healthcare systems.

IPMG members and their headquarters continue to invest in research and development to provide Indonesia with the latest medical innovations, which are safe and on par with international standards of quality. The safety and quality of our medicines have been proven through extensive clinical trials at our certified, state-of-the-art manufacturing facilities.

While striving to provide Indonesians with full access to innovative medicines, IPMG members respect and comply with the prevailing laws and regulations in Indonesia and keep their business in line with the highest ethical marketing codes.

IPMG member companies also actively engage with local communities, support local health programs, and carry out public education campaigns on diseases and health promotion. Meanwhile, as an active member of KADIN, MIAP, and IFPMA, IPMG reaches out to the public and other stakeholders through the regular issuance of quality content (press releases and position papers) and through its website.

IPMG members have introduced more than 900 state-of-the-art products into Indonesia to treat cancer, infectious diseases, cardiovascular diseases, and other diseases. IPMG members currently employ over 10,000 Indonesians in their operations.

Chairman Message



Ait-Allah Mejri
Chairman

At IPMG companies, our people go to work every day with the mission of making innovative treatments and potential cures accessible to all Indonesian patients. This goal is more important now than ever as we continue to face the Coronavirus pandemic. We remain committed to combating this public health crisis, and helping shape a future where patients' welfare is paramount and our support to them infallible.

We continue to stand firmly behind the medicines that we develop and the value they provide to patients and to Indonesia's healthcare system.

A Year Like No Other

2020 has proven to be a year like no other for our industry. The continuing global pandemic has impacted billions of people, cost more than two million lives and caused a massive economic setback worldwide. Never in recent memory has there been such a huge amount of political, media and therefore public interest in the pharma industry as in the past nine months. Developing a vaccine was the only way to eradicate the threat of COVID-19; and incredibly enough, our industry lived up to the occasion. Only nine months after the pandemic began, a vaccine was delivered. This definitely represents the medical breakthrough of our lifetime; one we ought to celebrate.

Doing Our Share

In Indonesia, IPMG members have worked tirelessly with urgency, passion and purpose to contribute to the national response to COVID-19. They have joined hands with the national regulatory agency (BPOM), the academia and other health stakeholders to ensure continuity of supply for essential medicines and vaccines for patients with other diseases and underlying medical conditions. Further, they have used their medical expertise to support healthcare providers in their effort to manage the unprecedented and challenging work pressure they were experiencing due to the pandemic.

Companies involved in R&D for COVID-19 diagnostics have delivered high quality tests and scaled up the national capacity of diagnostics testing for COVID-19 patients in record time. A number of member companies have also contributed by donating medicines, facemasks, gloves, disinfectants, and personal protective equipment to healthcare workers.

“We are proud of the role that IPMG companies have played in the national fight against the pandemic.”

While overall sales of IPMG patented medicines have declined in 2020 as a result of the COVID-19 impact on diagnoses and prescriptions, we remain proud, however, of the efforts IPMG companies have consistently deployed and the role they have played in the fight against the pandemic.

Our Priorities in 2021

Indonesia is entering a decisive decade aimed towards achieving its bold 2030 agenda. The Government has recognized that the current healthcare situation will have little chance to help the country harness its potential. It recently set a new ambition to build a more sustainable healthcare model before 2030. This is IPMG's ambition too!

One cannot expect the public sector to shoulder the burden of directly providing the needed services alone. It will be unable to do so anyway, given the current realities. As a science-driven industry that aims to address some of the world's biggest healthcare challenges, our industry is uniquely positioned to be a partner of choice towards achieving sustainability in Indonesia. In 2021, we are committed to continue working with the Government to enhance the value the health system produces, encourage adoption of innovation and technology; assist in the domestic journey to self-reliance; and, more importantly, help restore industry confidence through predictability, transparency and long-term partnerships.

We understand that self-sufficiency and non-reliance became the main goals of the Government. Yet we see ourselves as part of the solution.

We understand that our medicines must provide value for money and that in a world of finite resources, JKN cannot afford inefficient use of health spending. We also understand that self-sufficiency and non-reliance have become the

main goals of the Government. This is audible and laudable, yet we see ourselves as part of the solution and instrumental in bringing it to fruition.

Partners Not Foes

IPMG members in Indonesia have a long history of bringing innovation, fostering access, building a resilient regulatory system and strengthening domestic industry through partnerships and technology transfer.

This is their proudest achievement; however, Indonesia and the pharmaceutical industry are at a crossroads and cannot afford to turn the wrong way. We think what we should seek to change together is how we can work in partnership and how we can address some of our perception of collaboration challenges. These may have stemmed from divergent attitudes regarding certain policies and regulations that may have misunderstood or overlooked our concerns.

The bright promise of a healthier Indonesia will only be fulfilled if, together, we build, sustain and grow a social, economic and policy ecosystem that views health care not as a cost, but as an investment that is the foundation of a healthy and productive population and a more resilient economy. We must also meet the emerging challenges to our healthcare system arising from the increasing incidence of avoidable and treatable chronic conditions such as diabetes, heart disease and cancer.

Instead of being kept on the fringe of healthcare area and excluded from most policy-making processes, we call for greater and better engagement with all closest partners so that, together, we can build a stronger, more resilient health system and economy. Attaining this goal has to be a collaborative effort, requiring input from diverse stakeholders and key players in the industry. Collaboration has been our firm commitment and shall remain so.

Vision and Mission

To be a true partner towards Indonesia becoming a developed nation by 2045.

Role



IPMG is committed to working as a true partner of the Indonesian government in order to promote pro-growth and pro-innovation policies for the benefit of Indonesian patients and the economy.



We seek to uphold the highest ethical and safety standards and comply with all applicable domestic and foreign laws and regulations, consistent with the trust placed in our industry by patients and the public.



We will work together with the Indonesian government to achieve the best possible health outcome for citizens, while maintaining the sustainability of JKN and supporting the government's priority to develop the pharmaceutical industry.

IPMG's Commitment

Over the years, pharmaceutical companies have developed countless new drugs to manage diseases and mitigate patient suffering. With the specter of new diseases constantly on the horizon, this commitment to research and development is an ever-present imperative. IPMG members assume such responsibility with passion and commitment.

As an organization, IPMG is committed to working with all healthcare sector stakeholders and to fully supporting government programs and regulations. IPMG and its members assiduously strive to ensure Indonesians have access to quality healthcare products.

To ensure fair market practices, IPMG aims to create a favorable business climate, to adhere to existing government laws and regulations, and to uphold our Code of Ethical Practices.



IPMG's Commitment and Support for the Government of Indonesia in Handling COVID-19

IPMG members are committed to maintaining accessibility of drugs, not limited to those related to COVID-19, but also non-COVID medicines needed by patients with comorbidities and especially medicines for non-communicable diseases which can also save a patient's life.

IPMG members have contributed to the COVID-19 response beyond testing, clinical research and development by donating research kits to support the Eijkman Institute, providing personal protective equipment and medical supplies, as well as conducting capacity building for healthcare professionals regarding best practices in handling COVID-19.

COVID-19 Vaccine Progress

- Vaccine development usually takes around 15-20 years before it can be released in the market. However, in this unprecedented situation, with support from regulatory authorities and all other multilateral stakeholders, we are committed to making any vaccine developed through collaboration available and affordable through mechanisms offering fair access to people around the globe as soon as possible.
- Some companies (Sanofi, GSK, AstraZeneca, and Pfizer) – members of IPMG – are advancing our ongoing response to address COVID-19 by collaborating with a number of countries and multilateral organizations to make the vaccine widely accessible worldwide in an equitable manner.
- We believe global access to COVID-19 vaccines is a priority.
- We suggest further discussions regarding this matter are conducted by individual member companies, as they may have different implementation processes and timelines.

Photo by Jonathan Borba from Pexels

Governance

The Board of Supervisors is responsible for overseeing the association's management and operations in ensuring all policies and plans are implemented effectively. The Board of Management is responsible for the overall direction and performance of the Association. In carrying out its duties, the Executive Committee is supported by seven Sub-Committees and three Task Forces in charge of the following strategic areas:

- **Sub-Committees**

Communications, Commercial Excellence, Government Affairs, Market Access, Ethical Practices, Medical, and Regulatory

Each Sub-Committee has responsibilities and is led by a Chairperson appointed by the Board of Management.

- **Task Forces**

Halal, TKDN, and IP

These task forces are established to exclusively handle specific issues and to prepare input for advocacy purposes to the relevant stakeholders.

- **Forums**

HR and Procurement

Medium for IPMG members where ideas and views on a particular issue can be exchanged; their units do not need routine advocacy or activities.

The Secretariat serves as a point of contact for the Association's members and is tasked with the daily administration and management of the Association. The Treasurer ensures accounts and records of transactions are kept accordingly.

Board Composition

Board of Management



Ait-Allah Mejri
PT Roche Indonesia
Chairperson and Head of GA
Sub-Committee



Evie Yulin
PT Merck Indonesia Tbk
Vice Chairperson and Head of
Market Access Sub-Committee




Cyndy Galimpin
Boehringer Ingelheim Indonesia
Honorary Secretary Head of
Commercial Excellence Sub-
Committee



Jude Alexander
PT Astellas Indonesia
Honorary Treasurer



Anil Argilla
PT Pfizer Indonesia
Head of Communication
Sub-Committee



Joselito Sta-Ana
Sanofi Indonesia
Head of Medical Sub-Committee



Michael Angel Evangelista
PT Bayer Indonesia
Head of Ethical Practices Sub-Committee


Board of Supervisor



Anand Shetty
PT Novo Nordisk
Board of Supervisors Member



Selly Kartika
PT Abbott Indonesia
Board of Supervisors Member
and Head of Regulatory Affairs
Sub-Committee



George Stylianou
PT MSD Indonesia
Board of Supervisors Member

Board of Secretariat



Parulian Simanjuntak
parsi@indo.net.id
Executive Director



Suyanthi Zoelkifli
suyanthi.zoelkifli@ipmg-online.com
Communications Manager



Jony Dominggus
jony.dominggus@ipmg-online.com
Finance

The Secretariat



**International Pharmaceutical
Manufacturers Group (IPMG) Office**
Pondok Indah Office Tower 1, 1st Floor Suite 102
Jalan Sultan Iskandar Muda Kav V-TA
Pondok Indah, South Jakarta, Indonesia (12310)

Phone +62(21) 7697531
Fax +62(21) 7697532
Email ipmg@ipmg-online.com
Website www.ipmg-online.com
Twitter @ipmgonline

IPMG Member Companies







Photo by Magdiel Lagos on Unsplash

Activities and Contributions of Sub-Committees and Task Forces

Sub-Committee Activities
and Contributions



Photo by Rival Sitorus on Unsplash



Commercial Excellence Sub-Committee

Role

The Commercial Excellence Sub-Committee is responsible for supporting IPMG members with accurate periodical sales data from all member companies. The committee also guided the Commercial Teams of IPMG member companies on face-to-face and/or virtual activities during the onset of the pandemic and declaration of the PSBB in March 2020, including domestic travel for work.

Member(s)

Cyndy Galimpin (PT Boehringer Ingelheim Indonesia) – Chair

- | | |
|---|---|
| 1. Elna Frisnawaty Purba (PT Pfizer Indonesia) | 19. Vanco Pop-Petrovsky (Sanofi Group Indonesia) |
| 2. Myrna Mihardja (PT Pfizer Indonesia) | 20. Kevin Sukaria (PT Astra-Zeneca Indonesia) |
| 3. Dadik Jayadi (PT Pfizer Indonesia) | 21. Fitri Handayani (PT Boehringer Ingelheim Indonesia) |
| 4. Jamaludin (PT Eisai Indonesia) | 22. Argho Das (PT Boehringer Ingelheim Indonesia) |
| 5. Indiarti Maspateilla (PT Takeda Indonesia) | 23. Irlan Wahyu Sumirat (PT Novartis Indonesia) |
| 6. Nasriyanto Akhyar (PT Takeda Indonesia) | 24. Lili Wijata (PT Novartis Indonesia) |
| 7. Bambang Wisnu (GlaxoSmithKline Pharma) | 25. Arman Ssi (PT Transfarma Medica Indah) |
| 8. Gatit Sasanti (GlaxoSmithKline Pharma) | 26. Nursiana Rizkiansah (PT Transfarma Medica Indah) |
| 9. Cindiani Wulandari (PT Novo Nordisk Indonesia) | 27. Jenny Anggraeni Inaku (PT Merck Indonesia Tbk) |
| 10. Herlina Harjono (PT Novo Nordisk Indonesia) | 28. Fridayanti (PT Merck Indonesia Tbk) |
| 11. Gladys Samosir (PT Bayer Indonesia) | 29. Putri Christiani (PT Astellas Indonesia) |
| 12. Febby Ramaun (PT Roche Indonesia) | 30. Romi El Saladin (PT Astellas Indonesia) |
| 13. Fredy Soetioso (PT Roche Indonesia) | 31. Suzy Liana (PT Servier Indonesia) |
| 14. Putra Gunawan (PT Abbott Indonesia) | 32. Ambre Padeloup (PT Servier Indonesia) |
| 15. Sukmana Dwi Cahyadi (PT Abbott Indonesia) | 33. Asandra Padeloup (PT Servier Indonesia) |
| 16. Chairunnisa (PT Johnson & Johnson Indonesia) | 34. Daniel (PT MSD Indonesia) |
| 17. Arief Budi Santoso (PT Johnson & Johnson Indonesia) | |
| 18. Bina Argentahardi (Sanofi Group Indonesia) | |

Key Activities in 2020

Commercial Activities

- The COVID-19 pandemic has prompted the transition of face-to-face engagements to digital or other non-personal interactions.
- When the PSBB was declared in the 2nd week of March 2020, medical representatives and other customer facing roles of pharmaceutical companies engaged with HCPs mostly by phone. Some doctors reacted unfavorably (due to the high level of emotional uncertainty during the height of the pandemic).
- From the start of the PSBB, different hospitals and medical societies issued restrictions on MR visits and conducting events.
- Professionals Post PSBB / Movement Restrictions – Our New Normal – June 2020.
- Meeting with PT INMAR on IPMG iCloud Service to explore pre-work needed – November 2020.
- Commercial Excellence Sub-Committee Meeting, led by the Chair – November 30, 2020.
- Rolled out an initiative for market data improvement before migrating to iCloud Service – 2nd to 4th weeks of December 2020.
- Meeting with PT INMAR to discuss agreements of the CE members and discuss changes in naming conventions, timelines on iCloud services, hands-on training and implementation – Dec 2020.

Availability of Market / Sales Data

- IPMG members have raised concerns on different naming classifications of their own and/or competitor sales data. Gaps were compared to IQVIA's naming classification for different therapeutic classes and products.
- Issues on timeliness of monthly data submission and report availability.
- Need to update the data verification process and presentation, utilizing a more integrated platform.

Activities Accomplished in 2020

- Meeting with IQVIA: Some Insights on COVID-19 Impact to SEA from IQVIA Whitepaper & an Overview of IQVIA's New and Upcoming Solutions) – May 2020.
- Distributed guidelines to all IPMG companies – Ethical Considerations for Resuming Face-to-Face Interactions with Healthcare

Recommendations for 2021

- Finalize and execute the agreed therapeutic class naming classifications from IQVIA c/o PT INMAR – within Jan 2021.
- Set up a hands-on web-based training by PT INMAR for the onboarding of IPMG company members' representatives on how to upload and download the monthly report.
- Observe issues from monthly IPMG cloud-based market data and address when necessary. Sub-committee to provide further guidance as needed to commercial teams on the resumption of F2F events should it become necessary.
- On a needed basis, resolve issues related to IPMG member complaints / key issues and address in a company-to-company discussion.



Government Affairs Sub-Committee

Role

The Government Affairs Sub-Committee is responsible for creating and maintaining engagement platforms with stakeholders, as well as monitoring the legislation process. The Sub-Committee also proactively implements research policies to see what changes could influence the pharmaceuticals industry in the future.

Member(s)

Ait-Allah Mejri (PT Roche Indonesia) – Chair

Lucia Erniawati (PT Roche Indonesia) – Vice-Chair / Second-in-Command

1. Andri Kusandri (PT Merck Indonesia Tbk)
2. Bambang Chriswanto (PT Pfizer Indonesia)
3. Hanum Yahya (PT Novartis Indonesia)
4. Melanitri (PT Boehringer Ingelheim Indonesia)
5. Melisa Sandrianti (PT Merck Indonesia Tbk)
6. Farida Malawi (GlaxoSmithKline Pharma)
7. Lenny Santida (PT Roche Indonesia)
8. Rosalina Saleh (PT Novartis Indonesia)
9. Dani Priyono (Sanofi Group Indonesia)
10. Wanda Harahap (PT Abbott Indonesia)
11. Dudit Triyanto (PT Merck Sharp & Dohme Indonesia)
12. Banarsono Trimandojo (PT Novo Nordisk Indonesia)
13. Rizman Abudaeri (PT AstraZeneca Indonesia)

Key Activities in 2020

- Strengthened our partnership with government stakeholders, such as the Ministry of Health, the Presidential Staff Office, the Ministry of Industry, the Ministry of Law and Human Rights, the Ministry of Religious Affairs, BPOM, BKPM, BPJPH, and relevant stakeholders to focus on addressing opportunities across JKN, Halal Law for pharmaceuticals, patent-related issues, and Local Content Requirements (TKDN) for pharmaceuticals.
- Built our partnership and engagement with parliament stakeholders, such as Commission IX, the overseas health sector, Kaukus Kesehatan, MPR, and some DPR factions, to focus on advocacy of JKN-related policies and drug procurement as well as provide input for the Food and Drug Supervision Bill.
- Continued advocacy on mainstreaming non-

communicable disease treatment to both JKN's and the Ministry of Health's services.

- Continued advocacy on the implementation of Multiple Criteria Decision Analysis (MCDA) as part of JKN's drug procurement improvement by LKPP.
- Actively provided input and monitored the Omnibus Bill deliberation and its implementing regulations, especially with regard to business licensing, halal, and IPR.
- Supported the government through the Ministry of Health and BPOM with the readiness of IPMG members in supplying COVID-19 related drugs and non-COVID-19 drugs as well as supporting PPEs and other direct donations.
- Mainstreaming discussion on R&D industry with the Ministry of Health, the Ministry of Research and Technology, and the Coordinating Ministry for Maritime and Investment.
- Regularly monitored the Halal Law implementation and provided input for the Presidential Regulation draft.
- Active engagement and provision of technical support to strengthen IPR regulations.
- Promoted implementation of the Innovative Pricing model concept in JKN as the proposed solution to mitigate costs of non-communicable diseases in Indonesia.
- Regularly monitored and provided input on the Local Content Requirements that would affect the JKN drugs procurement.
- Strengthened IPMG's position as strategic partner and important stakeholder for any JKN discussion held by both the government and parliament.

Activities Accomplished in 2020

We engaged with stakeholders across key ministries and the parliament extensively throughout the year to build on our dialog focused on current policy considerations. The key ministries included:

1. The Ministry of Health (MoH)
2. The Coordinating Ministry of Economic Affairs (CMEA)
3. The Capital Investment of Coordinating (BKPM)
4. The Ministry of Industry (Mol)
5. The Ministry of Trade (MoT)
6. The National Development Planning Agency (Bappenas)

In addition to actively engaging with key stakeholders in Jakarta, we also strengthened communications with the organizations/associations to raise visibility on the proposed solutions/alternatives to current policies. The organizations/associations included:

1. US and European Embassies
 2. PhRMA
 3. AMCHAM
 4. EUROCHAM
 5. SWISSCHAM
 6. The US Chamber of Commerce
 7. The US Department of Trade
 8. The US-ASEAN Business Council
- Kick-off meeting, the establishment of IPMG Drug Working Committee (Tim Panja Obat IPMG) – January 22, 2020
 - Lead the development of the "Access for Unmet Medical Needs" press release with PKJS (Pusat Kajian Jaminan Sosial) – January 30, 2020, after FGD Market Access
 - Meeting with Bahlil Lahadalia, Chairman of the Investment Coordinating Board (BKPM) – March 4, 2020, with the following results:
 - + Strengthen the regulatory environment and revise regulations that hamper biopharmaceutical investment.
 - + Secure quick wins and invest long term by building human capital and R&D infrastructure.
 - + The government can drive R&D investment with a strong partnership



and support from IPMG.

- Hearing with Commission IX DPR RI – April 8, 2020, discussing drug access and availability during the COVID-19 pandemic
- Lead TKDN task force meeting for material preparation of LCR/TKDN advocacy points and narratives for meeting with MoH (Engko Sosialine) and Coordinating Ministry for Economic Affairs Deputy V (Ir. Bambang Adi Winarso) – June 12-15, 2020
- Meeting on TKDN/LCR advocacy with Deputy V of the Coordinating Ministry for Economic Affairs (CMEA), Ir. Bambang Adi Winarso – June 16, 2020
- Meeting on TKDN/LCR advocacy with Director General of Pharmaceuticals and Medical Devices of the MoH, Engko Sosialine – June 17, 2020
- Follow up meeting on LCR/TKDN advocacy with Assistant Deputy V of CMEA, Ichsan Zulkarnaen – June 19, 2020
- Government Affairs Subcommittee meeting Reshaping and Re-strengthening IPMG Engagement Strategy – August 13, 2020
- Alignment meeting for a call with Luhut Binsar Pandjaitan (Coordinating Minister for Maritime Affairs) and Investment & PhRMA – August 25, 2020
- Meeting with Dr. Bambang Brodjonegoro, Minister of Research and Technology – September 10, 2020
- Hearing with Commission IX DPR RI - Panja Obat (Drug Working Committee) – November 18, 2020



Recommendations for 2021

- Accelerate IPMG's positive value proposition with government stakeholders to strengthen IPMG's position as a strategic partner.
- Focus on promoting positive narratives, especially in the R&D industry to be the government and parliament's top-of-mind partner.
- Focus on providing strategic input with concrete solutions for some strategic issues, especially on drug availability through innovative financing.
- Provide concrete counsel and input on the TKDN mechanism, considering the R&D aspect and its investment.
- Proactively build and maintain good relationships with stakeholders by executing courtesy visits, as well as conducting several stakeholder forums and public hearings on some priority issues, i.e., JKN, halal, TKDN, patents.
- Strategically develop input to improve the drug management system through Commission IX, Kaukus Kesehatan, patient groups, and related government stakeholders.
- Continue positioning IPMG as a strategic partner for regulatory deliberations and discussions, including the BPOM Bill, the Pharmaceutical Bill, the Patent Law Revision, and the Omnibus Bill.
- Continue the educational campaign for the new parliament and new government stakeholder on IPMG's key priority issues and concerns.
- Develop/propose media advocacy to strengthen IPMG's advocacy on JKN, IP, and local content.
- Work closely with other associations, e.g., GP Farmasi, PhRMA, AmCham, EuroCham, APINDO, and KADIN, to provide the government with input and recommendations.



Ethical Practices Sub-Committee

Role

IPMG Ethical Practices Sub-Committee consists of 24 members from various international research-based companies. It is committed to the Indonesian medical and scientific community which complies with applicable laws and regulations. The Ethical Practices Sub-Committee consciously takes efforts to create a level playing field in the pharmaceutical industry by adopting stringent practices and taking compliance measures through its Code of Ethics as well as ensuring uniformity of interpretations and implementations. Working with relevant authorities and pharmaceutical stakeholders, the Ethical Practices Sub-Committee is improving health care services and benefiting patients in Indonesia.

Member(s)

Angel Michaelo Luna Evangelista (PT Bayer Indonesia) – Chair

1. Aprillia de Leon (PT Roche Indonesia)
2. Choon Jin Lim (PT AstraZeneca Indonesia)
3. Christanugra Philip (PT Transfarma Medica Indah)
4. Dewi Mayanita (PT Takeda Indonesia)
5. Dimas Adityo (Sanofi Group Indonesia)
6. Dinda Felia (PT Novo Nordisk Indonesia)
7. Elizabeth Apri Viciandari (PT GlaxoSmithKline)
8. Emidawati (PT Novartis Indonesia)
9. Fransisca Wardhani (PT Eisai Indonesia)
10. Jheani Kristy Artiningtias (GlaxoSmithKline Consumer Health)
11. Kamal Bahasuan (PT Mitsubishi Tanabe Pharma Indonesia)
12. Miranda Andamsari (PT Merck Tbk)
13. Ratna Palupi A (PT Bayer Indonesia)
14. Restiya Noviana (PT Anugerah Pharmindo Lestari)
15. Rosintan Manurung (PT Otsuka Indonesia)
16. Sidik Yudhi Rahmawan (PT Pfizer Indonesia)
17. Stephen Kenmer (Anugerah Pharmindo Lestari)
18. Sucipto Kuntoro (PT Astellas Pharma Indonesia)
19. Tantri Aprillia (PT Merck Sharp & Dohme Indonesia)
20. Tatang Purnawan (PT Mitsubishi Tanabe Pharma Indonesia)
21. Ute Nurdin Ramdani (PT Mitsubishi Tanabe Pharma Indonesia)
22. Wiratsari Pinastika (PT Boehringer Ingelheim Indonesia)
23. Yulia Sari (Johnson & Johnson Indonesia)

Key Activities and Contributions in 2020

- Appointed third party agency to review Fair Market Value for association fee, institution fee, and speaker/moderator fee.
- Socialized our Code of Ethical Practices to health care institutions/hospitals and medical associations.

Activities Accomplished in 2020

- Proactively established and built communication with the Ministry of Health and provided input and suggestions to the Ministry of Health's published Guidance Letter on Handling Institution's Approval during the COVID-19 outbreak.
- Discussion on providing meals to HCP via virtual meeting during the COVID-19 outbreak.

Recommendations for 2021

- Socialize Code of Ethics toward Member Company internal teams and external stakeholders, including an alliance with the Ministry of Health (MoH) and the Corruption Eradication Commission (KPK).
- Gain third-party support in setting up FMV (Fair Market Value) in relation to IPMG member companies' interaction with Health Care Professionals (HCPs) as a speaker, moderator, consultant, and advisory board member.
- Review articles in the IPMG Code of Ethics on virtual interactions and activities with HCP and HCO in anticipation of the digital marketing era.

Photo by National Cancer Institute on Unsplash





Regulatory Affairs Sub-Committee

Role

The Pharmaceutical Regulatory Sub-Committee is responsible for observing, communicating, and compiling/coordinating input from all IPMG member companies to the new policies, regulations or issues related to drug registration.

Member(s)

Selly Kartika (PT Abbott Indonesia) – Chair

Firnando Sianturi (PT Johnson & Johnson Indonesia) – Vice-Chair

1. Agustina Tjandra (PT Otsuka Indonesia)
2. Anna Emmy Kurniaty (PT AstraZeneca Indonesia)
3. Noorhayu Dhewayani (PT Bayer Indonesia)
4. Deny Yanes Souisa (PT Anugerah Pharmindo Lestari)
5. Destita Khairilisani (PT Abbott Indonesia) – Secretary
6. Emmy Cholida (PT Servier Indonesia)
7. Fatimah Ferial (Sanofi Group Indonesia)
8. Helly Tobing (PT Takeda Indonesia)
9. Henny Purwantini (PT Boehringer Ingelheim Indonesia) – IPRG Chairwoman
10. Marsela Lembayung (GlaxoSmithKline Pharma)
11. Meranti Puspitasari (PT Novartis Indonesia)
12. Iin Nurhayati (PT Pfizer Indonesia)
13. Rahmawati (PT Roche Indonesia)
14. Novita Widarisman (GlaxoSmithKline Sterling)
15. Widya Argarini (PT Merck Sharp & Dohme Indonesia)
16. Yasmin Juita (PT Abbott Indonesia)
17. Zulkifli (PT Eisai Indonesia)
18. Desti Wibowo (PT Merck Indonesia Tbk)



Key Activities and Contributions in 2020

Positioned IPMG as a partner of choice for local regulators (BPOM, MoH) by providing feedback, input, and insights on local drug regulatory processes and assisting to create solutions related to drug regulatory issues.

Activities Accomplished in 2020

- January 2020, provided input for BPOM regulation on Drug Information Standards
- February 2020, provided input for BPOM regulation on Drug Advertising Supervision Guidelines
- March 2020, provided input for BPOM regulation on Q&A Reliance Pathways
- September 2020, provided IFPMA with feedback on the analysis of emergency use procedures globally
- September 28, 2020, successfully participated and gave insights on hearing with Commission IX DPR-RI, themed Government Policies to Improve Availability of Drug Stock and Private Involvement in Fulfilling Drug Supply
- October 2020, orphan drug regulation proposal to BPOM, report proposal crafted by IPMG RA Sub-Committee and IPRG, vetted by IPMG Medical Sub-Committee
- November 2020, paperwork preparation for 10th APAC Conference (online) on April 13, 2021, organized by JPMA

Recommendations for 2021

- Continue monitoring development of new/revised draft regulations in BPOM/MOH.
- Provide input on the upcoming regulation and agenda, following current industry trends, e.g., implementation of e-labeling, real-world evidence (RWE), digital promotions, orphan drug guidelines, multi-drug sourcing (alternative/backup site), etc.
- Position IPMG as a partner of choice for key external stakeholders (BPOM, MoH) in terms of improving the drug's regulatory policy.



Medical Sub-Committee

Role

The IPMG Medical Sub-Committee is responsible for working on issues concerning medical, scientific, and educational activities, including research and development in the pharmaceutical field in Indonesia.

Member(s)

dr. Joselito Sta-Ana (Sanofi Group Indonesia) – Chair

dr. Fahad Jameel (PT Novo Nordisk Indonesia) – Vice-Chair

- | | |
|--|--|
| 1. dr. Ardini Kartasasmita (PT Taisho Pharmaceuticals Indonesia) | 7. dr. Edmond Maramis (PT Eisai Indonesia) |
| 2. dr. Budhy Damian Widjojo (PT Takeda Indonesia) | 8. dr. Handoko Santoso (PT Pfizer Indonesia) |
| 3. dr. David Sigit (PT Abbott Indonesia) | 9. dr. Mary Josephine (Sanofi Group Indonesia) |
| 4. dr. Deviyana (PT Transfarma Medica-Indah) | 10. dr. Calvin Kwan (GlaxoSmithKline Pharma) |
| 5. dr. Dewi Muliatin Santoso (PT Bayer Indonesia) | 11. dr. Richard Santoso (PT Novartis Indonesia) |
| 6. dr. Rospita Dian (PT Johnson & Johnson Indonesia) | 12. dr. Risa Anwar (PT Merck Indonesia Tbk) |
| | 13. dr. Stella Melissa (PT Astellas Pharma Indonesia) |
| | 14. dr. Temmy Winata (PT Boehringer Ingelheim Indonesia) |

Key Activities and Contributions in 2020

- Enabled local real-world evidence (RWE) generation and access to global clinical trials.
- Ensured FORNAS (National Formulary) aligned with PNPK (National Medical Services Guidelines).
- Secured alignment between BPOM/MoH and HCOs regarding unmet medical needs and role of innovative medicines.
- Collaborated with BPOM/MoH to improve adverse event reporting by HCPs in Indonesia.

Activities Accomplished in 2020

- Lead and drove “Using CSR Capital to Fight COVID-19 – PPE Donation for Medical Frontliners”. This initiative was held in March-May 2020, expanding to wider activities of not only donating PPE but all forms of CSR carried out by members to help combat the COVID-19 pandemic, with the following consolidated disbursed report:



- November 13, 2020, successfully conducted IPMG Medical Subcommittee's webinar, "Patient Care and Clinical Practice in the New Norm" – a partnership with IDI North Jakarta Branch, with speakers Dr. Fery Rahman, MKM, (IDI HO) Dr. Sally Aman Nasution, SpPD-KKV, FINASIM, FACP (PAPDI), and Dr. Dharmawan Ardi SpKJ (IDI North Jakarta Branch). Registered were 710 participants and 624 attendees, who completed the feedback survey at the end of the webinar.

Proposed 2021 Mission, Scope, and Future State

- Mission
 - + Advance the R&D landscape and pharmacovigilance in Indonesia

- Scope
 - + Strengthen clinical research capabilities, local real-world evidence (RWE) generation, and access to global clinical trials
 - + Improve adverse event reporting by HCPs in Indonesia
- Future State
 - + High-quality independent clinical research, relevant local RWE generation to address unmet needs, and a smooth approval process for global clinical trials
 - + Spontaneous reporting of adverse events by HCPs and an efficient management process



Market Access Sub-Committee

Role

The Market Access Sub-Committee is responsible for identifying policies and regulations related to the implementation of JKN – which might affect IPMG member companies and the entire pharmaceutical industry growth – as well as initiating advocacy efforts towards mitigating the possible negative impacts of the policies.

Member(s)

Evie Yulin (President Director of PT Merck Indonesia Tbk) – Vice-Chair and Head

Andri Kusandri (PT Merck Indonesia Tbk) – Main Coordinator

Rosalina Saleh (PT Novartis Indonesia) – Coordinator Health Care Financing Team

Lenny Santida (PT Roche Indonesia) – Coordinator JKN Drug Supply

- | | |
|--|---|
| 1. Andy Prabowo (PT Boehringer Ingelheim Indonesia) | 15. Rudy Firdaus (PT Eisai Indonesia) |
| 2. Melanitri (PT Boehringer Ingelheim Indonesia) | 16. Sasmito Hariwibowo (Sanofi Group Indonesia) |
| 3. Banarsono Trimandojo (PT Novo Nordisk Indonesia) | 17. Yulita Witantina (PT Merck Sharp & Dohme Indonesia) |
| 4. Bram Baan (GlaxoSmithKline Pharma) | 18. Haryati (PT Otsuka Indonesia) |
| 5. Dudit Triyanto (PT Merck Sharp & Dohme Indonesia) | 19. Antonius Catur Mariantio (PT Novartis Indonesia) |
| 6. Edi Rahman (PT Bayer Indonesia) | 20. Eko Wahyudi (PT Merck Indonesia Tbk) |
| 7. Widhi Jonathan (PT Abbott Indonesia) | 21. Wina Armawati (PT Mitsubishi-Tanabe Pharma Indonesia) |
| 8. Zacky Riskawa (GlaxoSmithKline Healthcare) | 22. Budi Suminto (PT Anugerah Pharmindo Lestari/APL) |
| 9. Bayu Erawan (PT Johnson & Johnson Indonesia) | 23. Antes Prasetyo (PT Mundipharma Healthcare Indonesia) |
| 10. Henny Mansjur (PT Johnson & Johnson Indonesia) | 24. Danika Adara Kartasasmita (PT Pfizer Indonesia) |
| 11. Lucia Erniawati (PT Roche Indonesia) | 25. Saanjay Shamdasani (PT Takeda Indonesia) |
| 12. Rizman Abudaeri (PT AstraZeneca Indonesia) | 26. Romi El Saladin (PT Astellas Indonesia) |
| 13. D. Hendriyan (PT AstraZeneca Indonesia) | |
| 14. Dias Kaderian Bachtiar (PT Novartis Indonesia) | |

Team Distribution

In 2020, the Market Access Sub-Committee took initiative to form an active team to focus on topics and issues related to healthcare financing and JKN drug supply.

Active JKN Drug Supply Members (Short-Term Program)

Lenny Santida (PT Roche Indonesia) – Coordinator

1. Banarsono Trimandojo (PT Novo Nordisk Indonesia)
2. Bram Baan (GlaxoSmithKline Pharma)
3. Edi Rahman (PT Bayer Indonesia)

Task Force Activities and Contributions

Focusing on current issues related to JKN listing and dynamic changes that had business impacts on the pharmaceutical industry.

- Active and continued advocacy addressing issues to improve the current tender process through expanded Multi Winner implementation.
- Engagement with stakeholders on improved JKN processes (i.e., Transparency of FORNAS process and pricing/HPS formation).

Active Healthcare Financing Members (Long-Term Program)

Rosalina Saleh (PT Novartis Indonesia) – Coordinator

1. Andy Prabowo (PT Boehringer Ingelheim Indonesia)
2. Henny Mansjur (PT Johnson & Johnson Indonesia)
3. Sasmito Hariwibowo (Sanofi Group Indonesia)

Task Force Activities and Contributions

Focusing on JKN sustainability issues and multiple stakeholders' involvement to ensure sustainable business impact.

- Advocacy and awareness activities on JKN financing, focusing on CoB (coordination of benefit).
- Active advocacy to create access to innovative medicines through innovative pricing model.
- HTA development and improvement in Indonesia – preliminary engagement.



Photo by National Cancer Institute on Unsplash

Activities Accomplished in 2020

Stakeholders Engagement

The Market Access Sub-Committee has engaged with key stakeholders to advocate issues on JKN sustainability (on improving drug supply in JKN and healthcare financing) through meetings / courtesy visits, FGDs, forums, and seminars. The list of activities which have been implemented is as follows:

9 January	Activities FGD on CoB in collaboration between IPMG and Pusat Kajian Jaminan Sosial UI (PKJS-UI) Key Topic(s) of Discussion(s) Access for Unmet Medical Needs: How to Make Innovative Medicines Accessible?	including medication. • IPMG suggested assessing innovative pricing models for a win-win solution for all parties. Team Involved Healthcare Financing
	Outcomes <ul style="list-style-type: none"> Recognition of the importance of cost effective analysis in medical services, 	

30 January	Activities Lead the development of the first press release on "Access for Unmet Medical Needs" together with PKJS Key Topic(s) of Discussion(s) Preparation and brainstorming of key messages for the press release after the FGD: Access for Unmet Medical Needs	Outcomes Development and finalization of the press release draft Teams Involved GA and Communications
----------------------	--	--

8 April	Activities Hearing with Commission IX DPR RI Key Topic(s) of Discussion(s) Discussion on drug access and availability during the COVID-19 Pandemic Outcomes <ul style="list-style-type: none"> Commission IX urges the MoH to coordinate with LKPP, and include GP Farmasi, IPMG, GAKESLAB, and ASPAKI to accelerate the national e-catalog and adjust the prices to ensure the supply of drug and medical devices for both COVID-19 and non-COVID-19 purposes. 	<ul style="list-style-type: none"> Commission IX urges the MoH to coordinate with the relevant ministries and agencies, including the National Police and regional governments, in ensuring the mobility of employees in the pharmaceutical and medical device industries and the distribution of goods are met, in accordance with MoH Reg. No 9/2020 on Large Scale Social Restriction Guidelines in Mitigating COVID-19. Team Involved All Market Access Sub-Committee
-------------------	---	--

16
June

Activities

Meeting with Deputy V of the Coordinating Ministry for Economic Affairs (CMEA), Ir. Bambang Adi Winarso

Key Topic(s) of Discussion(s)

TKDN/LCR Regulation Advocacy

Outcomes

Deputy V is open to learning and understanding the pharmaceutical industry. Ir. Bambang requested a more

detailed presentation as a follow-up and assigned Deputy V to synchronize line ministries' policies, including TKDN, while IPMG's concerns have been noted and will be discussed with MoI

Teams Involved

- IPMG
- MA Subcom

17
June

Activities

Meeting with Director General of Pharmaceuticals and Medical Devices, MoH, Engko Sosialine

Key Topic(s) of Discussion(s)

- TKDN/LCR Regulation Advocacy
- IPMG sought clarity on the implementation of TKDN/LCR in the 2021-2022 e-catalog

Outcomes

According to Engko Sosialine, TKDN/

LCR would be implemented in the tender process but would not apply in the negotiation process.

- The TKDN calculation would refer to the current regulation on TKDN/LCR.
- Multi-Winners will apply for a mass product as a new category.

Teams Involved

- Pak Anggi
- MA Subcom

10
September

Activities

Meeting with Dr. Bambang Brodjonegoro, Minister of Research and Technology

Key Topic(s) of Discussion(s)

- Collaboration and partnership with the international pharmaceutical industry to strengthen the ecosystem for healthcare and pharmaceutical investment in Indonesia.
- Formed a working group with government stakeholders to discuss and address key issues and challenges in healthcare and pharmaceutical investment in Indonesia, including in TKDN
- Collaboration with international pharmaceutical industry to commission a study to include health perspectives, such as quality

standards of medical practices, as well as health technology assessment (HTA)

Outcomes

- Minister Bambang was interested in discussing how to boost R&D and clinical trials in Indonesia and how IPMG members could contribute to more R&D, specifically phytopharmaceuticals and Modern Original Indonesian Medicine, or OMAI – Obat Modern Indonesia Asli.
- Minister Bambang was interested in how he and his ministry could help create conditions for R&D and clinical trials, seeking the best practices from other countries. Minister Bambang was much more interested in discussing how to boost R&D and

wanted to know more about IPMG's "900 innovative products" offering, and how its members could enter into research partnerships with the government.

- In discussing API imports, the Minister echoed other government officials' sentiment on reducing import substitutions. While IPMG explained that the nature of the pharmaceutical

value chain does not allow countries to be fully self-sufficient on local production of API, the minister said, "That's why we should also move forward with biopharmaceuticals and make use of Indonesia's biodiversity."

Teams Involved

- Board IPMG Member
- Sub Com Access

16
October

Activities

Courtesy meeting with Dita Novianti (MoH Yanfar Director)

Key Topic(s) of Discussion(s)

2021 FORNAS Review

- Review mechanism for 2021 FORNAS Review
- Clarity on FORNAS selection process, including the use of EBM, two-year MA limit
- New FORNAS Committee

Outcomes

- Dita Novianti explained that the MoH limits access to innovative medicines; however, considerations are due to the government's limited resources. She emphasized that pricing was not the main variable, but also cost-effectiveness and the outcomes generated by the medicines.

- The minimum two-year period for medicines to carry its NIE before being included in FORNAS is done to carefully study the safety profile and clinical experience of the drug. She welcomes additional studies and EBM which may help accelerate the process. She added that if there was an urgent requirement, the two-year rule could be overridden.
- New members to be included in the KOMNAS – Prof Rianto Setiabudy, Prof Erna (Erna Kristin), and Dr. Erwin (Erwin Astha Triyono) – will be included in the new KOMNAS, with the previous procedures still in effect based on existing regulations.

Team Involved

MA Subcom

21
October

Activities

Private Sector Engagement in Health Service Webinar Series. ANHSS, in collaboration with Center for Health Policy and Management – FK UGM, lead by Prof. Laksono, organized a knowledge transfer and capacity building course on private sector engagement

Key Topic(s) of Discussion(s)

Private insurance opportunity in the JKN Area

Outcomes

Some challenges in the private healthcare sector to harmonize the practice with JKN, since there is a difference in schemes (indemnity vs. managed care)

Teams Involved

- Executive Director of IPMG
- Healthcare financing team MA



Recommendations for 2021



Photo by ThisIsEngineering RAEng on Unsplash

JKN Drugs Supply

A. E-Catalogue Continuity and Tender Improvement

- Continue advocacy work and engage key policymakers and key stakeholders (MoH, LKPP, DPR, etc.) on the following:
 - + Fairness on TKDN Calculation
 - + Pricing (Self Estimation Price/HPS, price structure, innovative pricing scheme, free market price, multiple price scheme)
 - + Implementation and Gx categorization
 - + Transparency of the tender process

B. Transparency of JKN Listing Process

- Arrange an expert forum on the FORNAS Process (drug selection process/mechanism and pricing formation/structure). Discuss the following in the next FORNAS review:
 - + System/Mechanism to understand the rationale behind product acceptance/rejection on FORNAS list
 - + Transparency of pricing/HPS formation, including price structure pre-FORNAS listing

C. Implementation of JKN Standard Tariff

- Assess the impact of JKN Standard Tariff and develop mitigation plan/policy related to the implementation.
 - + Continue to engage DJSN and related stakeholders for JKN Standard Tariff
 - + Engage with MoH, Prof. Hasbullah, Prof. Leksono, medical associations, hospital associations, and related stakeholders for the implementation of KDK (Kebutuhan Dasar Kesehatan/Basic Health Needs)

Healthcare Financing

- Continue to Engage Stakeholders on CoB Implementation
 - + Continue engagement with PAMJAKI on the possibility of CoB implementation as a top up in the current JKN system, as well as anticipate the standard tariff implementation.
 - + Conduct FGD on CoB with PAMJAKI as host and invite respective stakeholders (MoH, BPJS, PERSSI, ARSSI, etc.)
- Access to Innovative Medicine Through Innovative Pricing Models
 - + Engage with LKPP, MoH, and BPKP to conduct FGD on access to innovative medicine and funding mechanisms, focusing on e-catalogue formulation in accommodating innovative pricing models.
- Partnership in HTA Roadmap Development
 - + Have preliminary engagement with the new HTA chairman and committee to start the partnership and develop HTA capabilities and roadmaps in Indonesia.



Photo by Viki Mohamad on Unsplash

Our Activities in 2020



Focus Group Discussion

Together with the University of Indonesia, IMPG held a Focus Group Discussion (FGD) on January 9, 2020, to discuss the “Access for Unmet Medical Needs: How to Make Innovative Medicine Accessible.”

NCDs are an increasing global challenge

- Most significant cause of death (71%) worldwide
→ 41 million people each year
- Each year, 15 million people die from a NCD between the ages of 30 and 69 years; over 85% of these "premature" deaths occur in **low- and middle-income countries**.
- Cardiovascular diseases** account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.0 million), respiratory diseases (3.9million), and diabetes (1.6 million).

2020-11-13 13:19:07

Dr. Sally: bagaimana meyakinkan pasien untuk mau kembali berobat / kontrol ke RS / pusat layanan kesehatan di masa pandemi mengingat banyak yg memiliki persepsi datang ke RS berisiko tertular covid?

Dr. Suryadi

5 VOTES

Ask your questions:
onpoint.pigeonhole.at/IPMGWEBINAR

Pigeonhole Live

2020-11-13 14:03:54

ISU GLOBAL BIDANG KESEHATAN

- NON COMMUNICABLE DISEASE**
 - Hipertensi
 - Diabetes
 - Kanker
 - Penyakit Paru Obstruktif
- PATIENT SAFETY**
 - Patient Centered Care
 - Medication Safety
 - Healthcare associated infection (HAI's)
- ANTIMICROBIAL RESISTANCE**
 - Ketidaktepatan Penggunaan Antibiotik
 - MDR-TB
- EMERGING AND RE-EMERGING DISEASE**
 - Perubahan Lingkungan
 - Evolusi Agent Infeksi
- UNIVERSAL HEALTH COVERAGE**

2020-11-13 13:37:44

Patient Care and Clinical Practice in the New Norm
Friday, 13 November 2020

Patient Care and Clinical Practice in the New Norm
Friday, 13 November 2020

Patient Care and Clinical Practice in the New Norm
Friday, 13 November 2020

Patient Care and Clinical Practice in the New Norm
Friday, 13 November 2020

Patient Care and Clinical Practice in the New Norm
Friday, 13 November 2020

Webinar

Together with IDI, IPMG held a webinar session discussing "Patient Care and Clinical Practice in the New Form" on November 13, 2020.

IPMG in the Media

INDUSTRI / MANUFAKTUR

Pelaku usaha soroti sanksi pidana yang tercantum pada RUU POM

Senin, 28 September 2020 / 21:12 WIB



ILUSTRASI. ilustrasi obat

Kontan.co.id

September 28, 2020

Pharmaceutical and herbal industry entrepreneurs highlighted the provisions of criminal sanctions for violations contained in the Draft Law (RUU) on Drug and Food Control (POM) at the DPR RI Commission IX General Hearing Meeting on Monday (28/9). Fernando, a representative of IPMG, also suggested aligning the POM Bill's sanctions with similar sanctions provisions in other regulations. Responding to all input, House of Representatives Commission IX Member of the Golkar Party faction, M. Yahya Zaini, stated that coaching should be a priority in the implementation of food and drug control.

Bisnis.com
April 8, 2020

IPMG Executive Director Parulian Simanjuntak stated at the BPOM virtual public hearing (RDPU) meeting with House of Representatives Commission IX on 8/4/2020 that the international pharmaceutical industry in Indonesia was committed to assisting the government in dealing with the COVID-19 outbreak. In response to the pandemic, IPMG helps supply drugs, diagnostic tools, personal protective equipment (PPE), and clinical research.

Home • Kabar24 • Nasional

Industri Farmasi Internasional Komitmen Bantu Pemerintah Lawan Covid-19

Parulian menyampaikan hal itu dalam rapat dengar pendapat umum (RDPU) BPOM dengan Komisi IX DPR, Rabu (8/4/2020) secara virtual.

Rayful Mudassir • Bisnis.com
08 April 2020 | 13:24 WIB



Direktur Eksekutif IPMG Parulian Simanjuntak - Facebook @parulianangsimanjuntak

Legislator: Gandeng perusahaan kesehatan, percepat penanganan COVID-19

O Jumat, 10 April 2020 12:11 WIB



Ilustrasi: Seorang Tenaga Kerja Indonesia (TKI) mengikuti Rapid Test COVID-19 ketika tiba dari Malaysia di Bandara Internasional Kualanamu Kabupaten Deli Serdang, Sumatera Utara. ANTARA FOTO/Seprienda Perdana/Rp

Antaranews.com

April 10, 2020

Sri Rahayu, Deputy Chairman of Commission IX of the Indonesian House of Representatives, expects the government to collaborate with industry associations to expedite the national e-catalog and ensure the availability of COVID-19 and non-COVID-19 drugs and medical devices. IPMG, as a health-related organization, is one of them.

Bisnis.com

April 8, 2020

Lucia Erniawati, a member of the IPMG Government Affairs Sub-Committee, requested – during a virtual public hearing (RDP) between BPOM and Commission IX of the House of Representatives on 8/4/2020 – the imposition of large-scale social restrictions (PSBB) in several areas to not hamper the distribution of drugs required by COVID-19 patients. IPMG also expects services for non-COVID-19 drugs to improve.

Home • Ekonomi & bisnis • Industri

Industri Farmasi Minta PSBB Tak Hambat Distribusi Obat Covid-19

Hal itu disampaikan Lucia Erniawati, anggota Sub Komite Government Affairs IPMG, dalam rapat dengar pendapat umum (RDP) BPOM dengan Komisi IX DPR RI yang berlangsung secara virtual, Rabu (8/4/2020).

Raykul Mudassir - Bisnis.com
08 April 2020 | 13:46 WIB



Lucia Erniawati, anggota Sub Komite Government Affairs IPMG - Facebook@luciaerniawati

IPMG on Media

BERITA BISNIS

RUU Pengawasan Obat Dibahas, Pengusaha Berharap Sanksi Pembinaan Ketimbang Pidana

Selasa, 29 September 2020 | 07:22 WIB



ILUSTRASI. GP Farmasi menilai, ketentuan sanksi administrasi dan pidana dalam draf RUU POM cenderung tidak proporsional dan berlebihan.

Kontan.co.id

September 29, 2020

The Food and Drug Control (POM) Bill (RUU) was brought back into discussion. Players in the pharmaceutical and herbal industries expect the criminal penalties outlined in Articles 98 and 99 of the POM Bill to be aligned with those outlined in Law Number 36 of 2009 on health. The discussion was rolled out in the DPR Commission IX General Hearing Meeting with IPMG and other pharmaceutical associations.

INDUSTRI

Sanksi di RUU Pengawasan Obat Bikin Ngeri Farmasi

Kontan Harian, **29 September 2020**

Harian Kontan

September 29, 2020

Discussions on the Food and Drug Control (POM) Bill (RUU) were back on track. This time, representatives from the pharmaceutical and herbal industries emphasized the draft regulation's criminal penalties' clauses. IPMG, as one of the pharmaceutical associations, also expressed its views.



***To be a true partner towards
Indonesia becoming a
developed nation by 2045.***

Glossary

A

ACPIA

ASEAN Confederation of
Pharmaceutical Industry
Associations

Amcham

American Chamber of
Commerce Indonesia

ANHSS

Asia-Pacific Network
for Health Systems
Strengthening

APAC

Asia Pacific

API Manufacturer

Active Pharmaceutical
Ingredients Manufacturer

APINDO

Indonesian Employers
Association

APRIA

ASEAN Pharmaceutical
Regulatory Industry
Association

ARSSI

Indonesian Private Hospital
Association

ASEAN

Association of Southeast
Asian Nations

ASPAKI

Indonesian Medical Device
Manufacturers Association

B

Bappenas

The National Development
Planning Board

BKPM

Investment Coordinating
Board

BPJPH

Halal Certification Agency

BPJS

Social Insurance Agency

BPKP

The Development Finance
Comptroller

BPOM

National Agency for Drugs and
Food Control

C

CoB

Coordination of Benefit

CE

Commercial Excellence

CHEPS

Center for Higher Education
Policy

CMEA

Coordinating Ministry of
Economic Affairs

D

Dinkes

Health Office

DJSN

Social Security Council

DPR

House of Representatives

E

EBM

Evidence-Based Medicine

Eurocham

European Business Chamber
of Commerce Indonesia

F

F2F

Face-to-Face

FGD

Focus Group Discussion

FMV

Fair Market Value

FORNAS

National Formulary

G

GDP

Gross Domestic Product

GP Farmasi

Indonesian Pharmaceutical
Companies Association

H

HCO

Health Care Organizations

HCP

Health Care Professional

HPS

Temporary Estimates of Price

HTA

Health Technology
Assessment

I

IASMED

The Indonesian Association
for the Study of Medicinals

IDI

Indonesian Medical
Association

IFPMA

Internal Federation
of Pharmaceutical
Manufacturers & Associations

IMERI

Indonesian Medical Education
and Research Institute

InaHEA

The Indonesian Health
Economic Association

IPMG

International Pharmaceutical
Manufacturers Group

IPR

Intellectual Property Rights

IPRG

International Pharmaceutical
Regulatory Group

J

JKN

National Health Insurance

JPMA

Japan Pharmaceutical
Manufacturers Association

K

KADIN

Indonesian Chamber of
Commerce

KDK

Basic Health Needs

Kemenko PMK

Coordinating Human
Development and Cultural
Ministry

KOMNAS

National Commissioner

KPK

Corruption Eradication
Commission

KSP

Presidential Staff Office

L

LKPP

State Procurement Agency

M

MCDA

Multiple Criteria for Decision
Analysis

MedReps

Medical Representatives

MIAP

Indonesian Anti Counterfeit
Society

MoH

Ministry of Health

MoI

Ministry of Industry

MoT

Ministry of Trade

MNC

Multi-National Corporations

MPR

People's Consultative
Assembly

MR

Medical Representative

MSL

Medical Science Liaison

P

P2JK

Financing and Health
Insurance Center

PAMJAKI

Indonesian Health Insurance
and Insurance Management
Association

PEDFI

Indonesian Pharmaceutical
Doctors Association

PERSI

Indonesian Hospital
Association

PhRMA

Pharmaceutical Research and
Manufacturers of America

PKJS

Social Security Research
Center

PNPK

National Medical Services
Guidelines

PPE

Personal Protective
Equipment

PSBB

Large Scale Social Restrictions

Puskesmas

Community Health Center

PV

Pharmacovigilance

R

R&D

Research and Development

RWE

Real-World Evidence

S

SEA

Southeast Asia

SJSN

National Social Security
System

SWISSCHAM

The Swiss-Indonesian
Chamber of Commerce

T

TKDN

Local Content Requirement

TNP2K

National Team for the
Acceleration of Poverty
Reduction

U

UMSP

Minimum Provincial Wage for
Different Sectors

Annual Report 2020

International Pharmaceutical Manufacturers Group (IPMG)

Pondok Indah Office Tower 1, 1st Floor Suite 102

Jalan Sultan Iskandar Muda Kav V-TA

Pondok Indah, South Jakarta, Indonesia (12310)



Phone +62(21) 7697531



Fax +62(21) 7697532



Email ipmg@ipmg-online.com



Website www.ipmg-online.com



Twitter [@ipmgonline](https://twitter.com/ipmgonline)